Jardiance (empagliflozin) is a type 2 diabetes oral medication in the SGLT-2 inhibitor class of drugs. Blocks glucose from being reabsorbed by the kidneys. Excess glucose is released in the urine, lowering blood glucose. Medications in the SGLT-2 inhibitor class may offer heart and kidney benefits for people with cardiovascular disease.
This medicine is approved for treating type 2 diabetes in adults and children 10 years and older.
It is also approved reducing the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, adults with heart failure, and adults with chronic kidney disease. It is not for treating type 1 diabetes.
- Jardiance helps to manage blood glucose levels in people with type 2 diabetes.
- Medications like Jardiance may offer heart and kidney benefits for people with cardiovascular disease.
- Taken with or without food, Jardiance is a tablet usually taken by mouth once daily in the morning.
- For people with type 2 diabetes, an initial dose of Jardiance is usually 10 mg.
- Common side effects may include increased urinary frequency, dizziness, and genital yeast infections.
Jardiance Specs
Key specification
General Information
Other Devices & Supplies
Looking for a different way to manage diabetes care? Browse and compare information on the latest devices, tools, and technology.
